Albany, NY -- (SBWIRE) -- 10/18/2019 -- Immune Thrombocytopenia Market Insights, Epidemiology and Market Forecast-2028

1. Total Immune Thrombocytopenia prevalent population in 7 major markets is approximately 180,498 in 2017.
2. The total diagnosed Immune Thrombocytopenia prevalent cases in 7MM is estimated to be approximately 147,174 in 2017.
3. In 2017, there were around 63,725 Immune thrombocytopenia prevalent cases and approximately 53,362 diagnosed Immune thrombocytopenia prevalent cases in the United States. Out of the total diagnosed cases, approximately 49,640 cases account for adult Immune thrombocytopenia and approximately 3,723 cases were diagnosed Immune thrombocytopenia prevalence population in children in 2017 in the United States.

(Albany, US)DelveInsight launched a new report on Immune Thrombocytopenia Market Insights, Epidemiology and Market Forecast-2028

Key benefits

1. Immune Thrombocytopenia market report covers a descriptive overview and comprehensive insight of the Immune Thrombocytopenia epidemiology and Immune Thrombocytopenia market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Immune Thrombocytopenia market report provides insights on the current and emerging therapies.
3. Immune Thrombocytopenia market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Immune Thrombocytopenia market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Immune Thrombocytopenia market.

Request for sample pages

"There was a total of approximately 32,364 female and around 20,998 male diagnosed cases of Immune Thrombocytopenia in 2017 in the United States."

The United States accounts for the highest Immune Thrombocytopenia market size in comparison to the other major markets i.e., EU5 countries (the United Kingdom, Germany, Italy, France, and Spain), and Japan. Among the EU5 countries, UK had the highest Immune Thrombocytopenia market size in 2017, while Spain had the lowest Immune Thrombocytopenia market size.
From 2023, the Immune Thrombocytopenia market value will start declining due to the patent expiration and subsequent launch of generic/biosimilar of nplate and promacta. So till, 2022 doptelet will continue to compete with both these drugs and after the patent expiry doptelet will not have any competitor in market. Apart from TPO?RAs, various drugs like, Takecab, Nexium capsules are approved in Japan that are indicated for the eradication of Helicobacter pylori in patients with idiopathic thrombocytopenic purpura.
The major goal for Immune Thrombocytopenia treatment is to provide a platelet count that prevents major bleeding rather than correcting the platelet count to normal levels. The management of Immune Thrombocytopenia varies widely and current international guidelines recommend several first? and second?line options, including some medicinal products that have not been approved in the EU for this particular condition.
At present, there have been few well?designed randomized trials targeted at reducing chronic Immune Thrombocytopenia in adults and children. Further prospective trials may be able to enhance the approach and improve overall outcomes. Adequate long?term follow?up will be necessary to determine whether relapse is truly averted or simply delayed. It will also be important to select novel composite outcomes that account for clinical events as well as evaluate the cost and the added adverse events of combined therapies.
In addition to clinical trials, essential research should focus on identifying patients who would benefit from more intensive therapy: for example, the ability to determine those patients who will develop persistent or chronic Immune Thrombocytopenia or identification of markers predictive of who would benefit most from a specific therapy.

The launch of the emerging therapies is expected to significantly impact Immune Thrombocytopenia treatment scenario in the upcoming years:-
Drugs covered
1. BT?595
2. GC5107A
3. LIV?Gamma SN Inj
4. Hetrombopag Olamine
5. Efgartigimod (ARGX?113)
And many others

The key players in Immune Thrombocytopenia market are:
1. Biotest
2. GC Pharma
3. SK Plasma
4. Jiangsu HengRui Medicine
5. Argenx
And many others

Table of contents

1. Key Insights
2. Immune Thrombocytopenia Market Overview at a Glance
3. Immune Thrombocytopenia Disease Background and Overview
4. Immune Thrombocytopenia Epidemiology and Patient Population
5. Country Wise Immune Thrombocytopenia Epidemiology
5.1. United States Epidemiology
5.2. EU5 Epidemiology
5.2.1. Germany
5.2.2. France
5.2.3. Italy
5.2.4. Spain
5.2.5. United Kingdom
5.3. Japan Epidemiology
6. Immune Thrombocytopenia Treatment and Management
7. Unmet Needs
8. Immune Thrombocytopenia Marketed Drugs
8.1. Key Cross Competition
8.2. Octagam: Octapharma USA
8.3. Nplate (AMG?531): Amgen
8.4. Privigen: CSL Behring
8.5. Rhophylac: CSL Behring
8.6. Doptelet (Avatrombopag): Dova Pharmaceuticals
8.7. Tavalisse (fostamatinib disodium hexahydrate): Rigel Pharmaceuticals
8.8. Rituximab: Zenyaku Kogyo/Biogen Idec
8.9. Promacta (eltrombopag): Novartis
8.10.Gammaplex: Bio Products Laboratory's
8.11. Takecab: Takeda Pharmaceutical Company Limited
8.12.Nexium Capsules: AstraZeneca
9. Immune Thrombocytopenia Emerging Drugs
9.1. Key Cross Competition
9.2. BT?595: Biotest
9.3. GC5107A: GC Pharma
9.4. LIV?Gamma SN Inj.: SK Plasma
9.5. Hetrombopag Olamine: Jiangsu HengRui Medicine
9.6. Efgartigimod (ARGX?113): Argenx
9.7. SKI?O?703: Genosco (a US?based subsidiary of Korean bio company Oscotec)
9.8. KZR?616: Kezar Life Sciences
9.9. Rozanolixizumab: UCB Biopharma
9.10. BMS?986004 (Letolizumab): Bristol?Myers Squibb
9.11. PRN?1008: Principia Biopharma
9.12. PRTX?100: Protalex
10. Immune Thrombocytopenia 7 Major Market Analysis
11. Market Outlook: The United States
11.1. United States Market Size
12. Market Outlook: Europe
12.1. Germany
12.2. France
12.3. Italy
12.4. Spain
12.5. United Kingdom
13. Market Outlook: Japan
14. Market Drivers
15. Market Barriers
16. Appendix
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:
Shruti Thakur
info@delveinsight.com
+919650213330
SOURCE DelveInsight